XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 22.02.2024

Das Instrument EN9 SE0003943620 ENZYMATICA AB EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024
The instrument EN9 SE0003943620 ENZYMATICA AB EQUITY is traded ex capital adjustment on 22.02.2024

Das Instrument D6Z NO0012547308 STANDARD SUPPLY NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument D6Z NO0012547308 STANDARD SUPPLY NK -,10 EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument 4YD SE0005454873 NANOLOGICA AB EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument 4YD SE0005454873 NANOLOGICA AB EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument 7XB SE0007789409 XBRANE BIOPHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument 7XB SE0007789409 XBRANE BIOPHARMA AB EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument A2S1 BMG0620W2019 ASIAN CITRUS HLDGS HD-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024
The instrument A2S1 BMG0620W2019 ASIAN CITRUS HLDGS HD-,01 EQUITY is traded ex capital adjustment on 22.02.2024

Treibt Nvidias KI-Boom den Uranpreis?

In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.

Hier klicken

Zeit	Aktuelle Nachrichten
Fr	ASIAN CITRUS (00073): DISCLOSEABLE TRANSACTION IN RESPECT OF THE DISPOSAL OF LISTED SECURITIES
29.10.	ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT
29.10.	ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT
29.10.	ASIAN CITRUS (00073): ANNUAL REPORT 2023/24
09.10.	ASIAN CITRUS (00073): DISCLOSEABLE TRANSACTION IN RESPECT OF ACQUISITION OF LISTED SECURITIES

Zeit

Aktuelle Nachrichten

ASIAN CITRUS (00073): DISCLOSEABLE TRANSACTION IN RESPECT OF THE DISPOSAL OF LISTED SECURITIES

29.10.

ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT

29.10.

ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT

29.10.

ASIAN CITRUS (00073): ANNUAL REPORT 2023/24

09.10.

ASIAN CITRUS (00073): DISCLOSEABLE TRANSACTION IN RESPECT OF ACQUISITION OF LISTED SECURITIES

Zeit	Aktuelle Nachrichten
07.11.	Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets	LUND, Sweden, Nov. 7, 2024 /PRNewswire/ -- Third quarter January-September Net sales reached SEK 12.6 (13.3) million. The operating result totaled... ► Artikel lesen
12.09.	ENZYMATICA AB: Enzymatica announces outcome of new rights issue
12.09.	ENZYMATICA AB: Final study results - ColdZyme reduces illness duration and alleviates symptoms
09.09.	ENZYMATICA AB: Enzymatica publishes supplementary prospectus
05.09.	ENZYMATICA AB: Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

Zeit

Aktuelle Nachrichten

07.11.

Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets

LUND, Sweden, Nov. 7, 2024 /PRNewswire/ -- Third quarter January-September Net sales reached SEK 12.6 (13.3) million. The operating result totaled...
► Artikel lesen

12.09.

ENZYMATICA AB: Enzymatica announces outcome of new rights issue

12.09.

ENZYMATICA AB: Final study results - ColdZyme reduces illness duration and alleviates symptoms

09.09.

ENZYMATICA AB: Enzymatica publishes supplementary prospectus

05.09.

ENZYMATICA AB: Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

Zeit	Aktuelle Nachrichten
08.11.	Nanologica AB: Interim Report Q3 2024 Nanologica AB (publ)	FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) • Operating loss for the quarter amounted to SEK -22... ► Artikel lesen
23.09.	XFRA CAPITAL ADJUSTMENT INFORMATION - 23.09.2024	Das Instrument GI11 US36467X2062 GAMING INNOVATION DL 1 EQUITY wird cum Kapitalmassnahme gehandelt am 23.09.2024 und ex Kapitalmassnahme am 24.09.2024 The instrument GI11 US36467X2062 GAMING INNOVATION... ► Artikel lesen
29.08.	Nanologica AB: Nanologica Resolves On A Fully Underwritten Rights Issue Of Units Of Approx. Sek 99.4 Million, An Over-allotment Issue Of Up To Sek 20 Million, And Raises Bridge Loans Of Sek 15 Million	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION... ► Artikel lesen
05.07.	Nanologica AB: Interim Report Q2 2024 Nanologica AB (publ)	FINANCIAL SUMMARY • Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) • Operating loss for the quarter amounted to SEK -9,832... ► Artikel lesen

Zeit

Aktuelle Nachrichten

08.11.

Nanologica AB: Interim Report Q3 2024 Nanologica AB (publ)

FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) • Operating loss for the quarter amounted to SEK -22...
► Artikel lesen

23.09.

XFRA CAPITAL ADJUSTMENT INFORMATION - 23.09.2024

Das Instrument GI11 US36467X2062 GAMING INNOVATION DL 1 EQUITY wird cum Kapitalmassnahme gehandelt am 23.09.2024 und ex Kapitalmassnahme am 24.09.2024 The instrument GI11 US36467X2062 GAMING INNOVATION...
► Artikel lesen

29.08.

Nanologica AB: Nanologica Resolves On A Fully Underwritten Rights Issue Of Units Of Approx. Sek 99.4 Million, An Over-allotment Issue Of Up To Sek 20 Million, And Raises Bridge Loans Of Sek 15 Million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION...
► Artikel lesen

05.07.

Nanologica AB: Interim Report Q2 2024 Nanologica AB (publ)

FINANCIAL SUMMARY • Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) • Operating loss for the quarter amounted to SEK -9,832...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Fr	Standard Supply AS: STSU - THIRD QUARTER 2024 financial results
30.10.	XFRA D6Z0: WIEDERAUFNAHME/RESUMPTION	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen
30.10.	XFRA D6Z0: AUSSETZUNG/SUSPENSION	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSTANDARD SUPPLY... ► Artikel lesen
30.10.	XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 30.10.2024	The following instruments on XETRA do have their first trading 30.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.10.2024 Aktien 1 PLTRKPL00014 Trakcja S.A. 2 GB00BPVDXX64... ► Artikel lesen
29.10.	XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 29.10.2024	The following instruments on Boerse Frankfurt do have their last trading day on 29.10.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 29.10.2024.ISIN NameNO0012547308 STANDARD... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Standard Supply AS: STSU - THIRD QUARTER 2024 financial results

30.10.

XFRA D6Z0: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen

30.10.

XFRA D6Z0: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSTANDARD SUPPLY...
► Artikel lesen

30.10.

XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 30.10.2024

The following instruments on XETRA do have their first trading 30.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.10.2024 Aktien 1 PLTRKPL00014 Trakcja S.A. 2 GB00BPVDXX64...
► Artikel lesen

29.10.

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 29.10.2024

The following instruments on Boerse Frankfurt do have their last trading day on 29.10.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 29.10.2024.ISIN NameNO0012547308 STANDARD...
► Artikel lesen

Zeit	Aktuelle Nachrichten
24.10.	Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2024	Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWTHIRD QUARTER 2024*• Revenue... ► Artikel lesen
21.10.	Xbrane Biopharma AB: Xbrane Provides Update On The Ongoing Out-licensing Of Xdivane (nivolumab Biosimilar Candidate) And Xb003 (cimzia Biosimilar Candidate) And Its Financial Position	Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") is, as communicated on August 12th, actively seeking partners for its biosimilar candidates Xdivane and XB003. The company has reached agreement... ► Artikel lesen
27.09.	Xbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)	Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo® biosimilar candidate Xdivane. FDA... ► Artikel lesen
28.08.	Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2024	Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2024*• Revenue amounted... ► Artikel lesen
12.08.	Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status	Idag, den 12 augusti 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") ett pressmeddelande med information om att Bolagets rörelsekapital beräknas räcka till slutet av oktober 2024. Enligt regelverket... ► Artikel lesen

Zeit

Aktuelle Nachrichten

24.10.

Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2024

Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWTHIRD QUARTER 2024*• Revenue...
► Artikel lesen

21.10.

Xbrane Biopharma AB: Xbrane Provides Update On The Ongoing Out-licensing Of Xdivane (nivolumab Biosimilar Candidate) And Xb003 (cimzia Biosimilar Candidate) And Its Financial Position

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") is, as communicated on August 12th, actively seeking partners for its biosimilar candidates Xdivane and XB003. The company has reached agreement...
► Artikel lesen

27.09.

Xbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo® biosimilar candidate Xdivane. FDA...
► Artikel lesen

28.08.

Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2024

Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2024*• Revenue amounted...
► Artikel lesen

12.08.

Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status

Idag, den 12 augusti 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") ett pressmeddelande med information om att Bolagets rörelsekapital beräknas räcka till slutet av oktober 2024. Enligt regelverket...
► Artikel lesen